Argenx clinical pipeline and sector peers, shares watched in biotech

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 20:18.

Argenx SE (NL0010832176) continues to draw attention in the biotech space as investors monitor the progress of its antibody pipeline targeting autoimmune diseases. The company is listed on Nasdaq under the ticker ARGX, providing exposure to the broader biotech segment alongside peers such as Regeneron and Roche.

Biotech positioning and pipeline focus

Argenx SE is a biotechnology company developing antibody-based therapies for severe autoimmune diseases and cancer, with its lead drug candidate efgartigimod already approved in generalized myasthenia gravis in several markets. The company collaborates with partners and runs multiple clinical trials, expanding its reach in autoimmune neurology and hematology.

The biotech sector includes prominent players like Regeneron, Roche and Novartis, which also focus on immunology and oncology, highlighting the competitive landscape for antibody treatments. Argenx SE shares offer investors exposure to this innovative but volatile segment of the healthcare market.

Sector peers and investor interest

Biotech stocks such as Regeneron, Roche and Novartis have reported ongoing developments in their immunology and oncology pipelines, underlining continuous innovation in the sector. Argenx SE operates within this environment, where clinical outcomes and regulatory decisions can significantly influence investor sentiment.

Argenx SE shares trade on Nasdaq, enabling international investors to participate in the company’s progress alongside other biotech listings. The focus on autoimmune diseases and antibody engineering aligns the company with global efforts to address high unmet medical needs in neurology and hematology.

What the company develops

Argenx SE builds a portfolio of antibody-based therapies that modulate immune pathways in autoimmune diseases and cancer. The company’s work includes candidates designed to target specific proteins involved in disease processes, reflecting a focus on precision medicine within the biotech industry.

The listing and current trading venue

Argenx SE stock trades on Nasdaq in New York, giving international investors access to its biotech pipeline through a major US exchange.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.